•  
  •  
 

Abstract

Background: Tamoxifen is an estrogen antagonist used as neo-adjuvant drug for breast cancer treatment in women.

Objective: To evaluate tamoxifen monotherapy on breast cancer for elderly women with estrogen positive, progesterone positive, and Her2/neu negative.

Materials and methods: Seventeen breast cancer women were examined. The age range of the patients was between 73 and 87 years (mean ± SD: 79.2 ± 3.8 years). The patients were examined and diagnosed by a surgeon, and histopathologic examination. The patients included in the study were estrogen positive, progesterone positive, and Her2/neu negative. The patients were treated with tamoxifen monotherapy 20 mg/day orally during the two-year study. The size of the tumor were measured by ultrasonic examination for each patient. Five milliliters (mL) of blood samples were taken from the patients and analyzed for CA15-3. The clinical and ultrasonic examination as well as blood investigations were carried out every 3 months for two years, while only clinical examinations were continued every six months up to 5 years.

Results: Treatment of breast cancer women by tamoxifen 20 mg/day gradually decreased serum CA15-3 significantly (p ≤ 0.01) every 3 months. After two years of treatment with tamoxifen, serum CA15-3 was within normal range. The size of the tumor was decreased significantly and gradually every 3 months. After two years the tumor was completely disappeared. Each parameter was compared with that parameter measured before 3 months. Lymph node positive patients were 11 out of 17 patients; however, after 21 months of tamoxifen treatment, all patients were lymph node negative.

Conclusion: Tamoxifen monotherapy can be used for the treatment of women with breast cancer with estrogen +, progesterone + and Her2/neu–. The program can be applied for elderly breast cancer women or incompliance patients.

First Page

34

Last Page

37

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Share

COinS